Format

Send to

Choose Destination
Int J Hematol. 2006 May;83(4):289-93.

New strategies in chronic myeloid leukemia.

Author information

1
Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org

Abstract

Most patients with chronic myeloid leukemia (CML) achieve clinically relevant hematologic and cytogenetic responses to imatinib. Patients who show resistance to imatinib need new therapeutic options. A range of options are being developed to treat imatinib-resistant patients who have CML. Promising results of early-phase clinical trials have been reported for new tyrosine kinase inhibitors, farnesyl transferase inhibitors, decitabine, homoharringtonine, and vaccines. Further clinical trials are needed to characterize the efficacy and safety profile of these new agents and to determine which agents improve the long-term prognosis for patients with CML who have shown resistance to imatinib.

PMID:
16757426
DOI:
10.1532/IJH97.06024
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center